OncoSec Medical Inc (ONCSQ)

[hschlauch]

Hey everyone I found this quite interesting and relevant...

http://www.marketwired.com/press-release/dynavax-presents-updated-data-sd-101-combination-with-keytrudar-pembrolizumab-highlighting-2219983.htm

It looks like TLR9 and Keytruda are very effective in combination when treating all-comers, but can't achieve more than 17% ORR in anti-PD-1 nonresponders. Just keep this in perspective when ONCS data start to roll in. DVAX is up 20% on this news. They are taking the fight directly to the tumor, which is exactly where the PD-1 upregulation needs to occur and where tumor antigens are recognized to stimulate immune responses.

BERKELEY, CA--(Marketwired - June 02, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck, known as MSD outside the United States and Canada. Results evaluating 19 patients for efficacy and 22 patients for safety were presented in a poster at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago:

In 7 anti-PD-1/L1-naïve patients, SD-101 used in combination with KEYTRUDA resulted in an overall response rate (ORR) of 100%, with a complete response (CR) rate of 29%. This is a meaningful increase over use of KEYTRUDA alone, which has already shown a 33% ORR, with a 6% CR.

In 12 patients with advanced (stage IIIc/IV) melanoma who had previously failed on anti-PD-1 treatment, introduction of SD-101 resulted in tumor shrinkage in 42% of patients, with 17% having a partial response (PR), indicating an anti-tumor immune response generated by SD-101./quote]